Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Deregulation of the RAS GTPase cycle due to mutations in the three RAS genes is commonly associated with cancer development. Protein tyrosine phosphatase SHP2 promotes RAF-to-MAPK signaling pathway and is an essential factor in RAS-driven oncogenesis. Despite the emergence of SHP2 inhibitors for the treatment of cancers harbouring mutant KRAS, the mechanism underlying SHP2 activation of KRAS signaling remains unclear. Here we report tyrosyl-phosphorylation of endogenous RAS and demonstrate that KRAS phosphorylation via Src on Tyr32 and Tyr64 alters the conformation of switch I and II regions, which stalls multiple steps of the GTPase cycle and impairs binding to effectors. In contrast, SHP2 dephosphorylates KRAS, a process that is required to maintain dynamic canonical KRAS GTPase cycle. Notably, Src- and SHP2-mediated regulation of KRAS activity extends to oncogenic KRAS and the inhibition of SHP2 disrupts the phosphorylation cycle, shifting the equilibrium of the GTPase cycle towards the stalled ‘dark state’.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Fig. 5 Tyrosyl phosphorylation of KRAS disrupts GTPase cycle. a Overlay of four 1H-15N HSQC spectra of two representative residues T74 and M67, in which the four peaks represent GDP-loaded KRAS (black), GTP-loaded KRAS (blue), GDP-loaded Src-phosphorylated (p)KRAS (red), and GTP-loaded pKRAS (green). b Real-time NMR-derived nucleotide exchange curves for unmodified vs. Src-phosphorylated KRAS. A 250μM sample of GDP-loaded 15N KRAS (black) or pKRAS (blue) was incubated with ten-fold molar excess of GTPγS. Each dot represents mean fraction of KRAS that is loaded with GDP on the basis of peak intensities [IGDP/(IGDP + IGTPɣS)] from the same three residues of KRAS and pKRAS. SOScat was added at a ratio of 1:600 to KRAS (orange) or pKRAS (red). c Src phosphorylation of KRAS impairs SOScat-assisted nucleotide exchange. Fold increase in the rate of exchange upon addition of SOScat to KRAS or pKRAS. The reaction was performed twice in the absence and twice in the presence of SOScat and four ratios were determined from each pairwise comparison. d GTP hydrolysis curves illustrating intrinsic and RASA1 GAP domain (1:3000 ratio) assisted GTP hydrolysis for unmodified KRAS and pKRAS. e Src phosphorylation of KRAS reduces sensitivity to GAP activity. Fold increase in the rate of GTP hydrolysis with addition of RASA1 GAP domain for KRAS vs. pKRAS. The reaction was performed twice in the absence and twice in the presence of RASA1 GAP domain and four ratios were determined from each pairwise comparison. b, d present a single representative experiment that was repeated at least twice. Error bars represent the standard deviation of the fraction GDP as reported by three pairs of cross-peaks. Error bars in c, e indicate standard deviation of the fold changes](https://figures.cochat.ai/paper-figures/c3bdcb710586444985039792682bd403/tyrosyl-phosphorylation-of-kras-stalls-gtpase-cycle-via-alteration-of-switch-i-figure-5.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Blocking SHP2 prevents the loading of GTP into the RAS, and it is aimed to provide anticancer activity in this way [68,69].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [69]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“SHP2 is a protein tyrosine phosphatase that promotes RAS signaling through multiple mechanisms, including facilitation of SOS1-mediated nucleotide exchange and regulation of KRAS conformational dynamics through dephosphorylation of Tyr32 and Tyr64 [8,9].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [8]
In the citing paper
“Src homology region 2 domain-containing phosphatase 2 (SHP2) is a receptor-free protein-tyrosine phosphatase and regulates proliferation by activating the RAS–MAPK–ERK signaling pathway.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NMRPipe: A multidimensional spectral processing system based on UNIX pipes
Delaglio, F., Grzesiek, S., Vuister, G., Zhu, G., Pfeifer, J., & Bax, A. (1995) · Journal of Biomolecular NMR · doi:10.1007/bf00197809 · Cited by 15,965
Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885
Moffitt, R. A., Marayati, R., Flate, E. L., Volmar, K. E., Loeza, S. G. H., Hoadley, K. A., Rashid, N. U., Williams, L. A., Eaton, S. C., Chung, A. H., et al. (2015) · Nature Genetics · doi:10.1038/ng.3398 · Cited by 2,194
Self-citationOrganoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150
NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy
Lee, W., Tonelli, M., & Markley, J. L. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu830 · Cited by 2,045
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543
Increasing complexity of Ras signaling
Campbell, S. L., Khosravi-Far, R., Rossman, K. L., Clark, G. J., & Der, C. J. (1998) · Oncogene · doi:10.1038/sj.onc.1202174 · Cited by 1,079
Pai, E. F., Krengel, U., Petsko, G. A., Goody, R. S., Kabsch, W., & Wittinghofer, A. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07409.x · Cited by 1,074
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Chen, Y.-N. P., LaMarche, M. J., Chan, H. M., Fekkes, P., Garcia-Fortanet, J., Acker, M. G., Antonakos, B., Chen, C. H.-T., Chen, Z., Cooke, V. G., et al. (2016) · Nature · doi:10.1038/nature18621 · Cited by 925
Cited by
Pan-KRAS Inhibitor Disables Oncogenic Signalling and Tumour Growth
Kim, D., Herdeis, L., Rudolph, D., Zhao, Y., Böttcher, J., Vides, A., Ayala-Santos, C. I., Pourfarjam, Y., Cuevas-Navarro, A., Xue, J. Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06123-3 · Cited by 534
The current understanding of KRAS protein structure and dynamics
Pantsar, T. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.12.004 · Cited by 282
“The tyrosine residues Y32 and Y64, in switch-I and switch-II, respectively, can be phosphorylated via c-Src [80].”
BackgroundApplication of Fragment-Based Drug Discovery to Versatile Targets
Li, Q. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00180 · Cited by 198
Therapeutic targeting of RAS: New hope for drugging the “undruggable”
Khan, I., Rhett, J. M., & O'Bryan, J. P. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.118570 · Cited by 110
“In a recent study, Src was shown to directly phosphorylate KRAS on Tyr32 and Tyr64, altering the conformations of SW1 and SW2, respectively [47].”
BackgroundVainonen, J. P., Momeny, M., & Westermarck, J. K. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe2967 · Cited by 117
Metadata
- Authors
- Kano, Y., Gebregiworgis, T., Marshall, C. B., Radulovich, N., Poon, B. P. K., St-Germain, J., Cook, J. D., Valencia-Sama, I., Grant, B. M. M., Herrera, S. G., Miao, J., Raught, B., Irwin, M. S., Lee, J. E., Yeh, J. J., Zhang, Z.-Y., Tsao, M.-S., Ikura, M., & Ohh, M.
- Affiliations
- University of Toronto (CA)
- University Health Network (CA)
- University of North Carolina at Chapel Hill (US)
- Purdue University West Lafayette (US)
- Hospital for Sick Children (CA)
- Corresponding author
- Ohh, Michael
- ORCID
- Venue
- Nature Communications
- Published
- 2019-01-15
- Volume
- 10
- Issue
- 1
- Pages
- 224-224
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC6333830
- OpenAlex
- W2909726024
- Cited by
- 103
- References
- 68
- Citations by year
- 2026: 12 · 2025: 8 · 2024: 16 · 2023: 14 · 2022: 20 · 2021: 13 · 2020: 14 · 2019: 6
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- UNC Libraries
- Funders
- Cancer Research Society
- University of Toronto
- National Institutes of Health (RO1 CA207288)
- Canadian Institutes of Health Research (FDN‐1542284)
- Canadian Cancer Society Research Institute (703209)
- Japan Society for the Promotion of Science
- National Cancer Institute (R01CA207288, R01CA199064)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Keywords
- KRAS, tyrosine phosphorylation, SHP2, Src kinase, oncogenic KRAS, SHP2 inhibitors, dark states, MAPK signaling
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Male, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Mice, SCID, GTP Phosphohydrolases, Carcinoma, Pancreatic Ductal, Xenograft Model Antitumor Assays, raf Kinases, Protein Tyrosine Phosphatase, Non-Receptor Type 11, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation. https://app.cochat.ai/papers/10.1038/s41467-018-08115-8
- The paper
- Kano, Y., Gebregiworgis, T., Marshall, C. B., Radulovich, N., Poon, B. P. K., St-Germain, J., Cook, J. D., Valencia-Sama, I., Grant, B. M. M., Herrera, S. G., Miao, J., Raught, B., Irwin, M. S., Lee, J. E., Yeh, J. J., Zhang, Z.-Y., Tsao, M.-S., Ikura, M., & Ohh, M. (2019). Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation. Nature Communications. https://doi.org/10.1038/s41467-018-08115-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.